Peripheral Nerve Blocks in Ambulatory Surgery: sPNB vs. cPNB
The infographic illustrates the fundamental neuroscience and practical comparison of two regional anaesthetic strategies. Pain signals originate from peripheral nociceptors, travel via nerve fibres, and pass through a metaphorical “pain gate” to reach conscious perception. Both single-shot peripheral nerve block (sPNB) and continuous peripheral nerve catheter (cPNB) interrupt this pathway by depositing local anaesthetic perineurally — the sPNB via a one-time ultrasound-guided injection, and the cPNB via an indwelling catheter connected to an elastomeric or electronic pump delivering ongoing anaesthetic flow.
The infographic then contrasts six key clinical dimensions:
| Domain | sPNB | cPNB |
|---|---|---|
| Pain relief duration | Hours (transient) | Days (extended) |
| Pain control quality | Possible “step-up” rebound pain | Smooth, uninterrupted comfort |
| Mobility | Greater early independence | Requires wearable pump |
| Technical complexity | Simple, fast placement | Skilled, time-intensive |
| Risk profile | Lower complication rate | Leakage, displacement risk |
| Best use | Minor/moderate pain procedures | Major/extensive pain procedures |
The decision framework rests on five key factors: surgery type, patient preference, the sPNB vs. cPNB balance, available home support, and cost/resources.
Clinical Expansion
1. Analgesic Efficacy Evidence
In a pooled analysis of 21 studies comparing cPNB to sPNB, worst VAS pain scores were significantly lower in patients receiving cPNB on postoperative days 0, 1, and 2 — but not by day 3. Opioid consumption was also significantly reduced. This makes the cPNB particularly valuable in the first 48 hours after major orthopaedic surgery.
For shoulder surgery specifically, pain control was superior with single-shot interscalene block (ISB) for up to 24 hours in 4 of 4 trials, and with continuous ISB for up to 48 hours in 2 of 2 trials.
In a landmark multicentre RCT published in the British Journal of Anaesthesia (2023), 294 patients were randomised to continuous perineural analgesia or single-injection nerve block for ambulatory orthopaedic surgery, with the primary outcome of patient-reported satisfaction assessed on postoperative Day 2. Crucially, poor early pain experience was independently associated with a significantly elevated risk of chronic post-surgical pain at 90 days — underscoring that the block choice carries long-term consequences.
2. The Rebound Pain Problem with sPNB
A clinically important but underappreciated hazard of sPNB is rebound pain — a sudden, intense pain surge as the block dissipates. Non-compliant bridging analgesic therapy is believed to be the leading cause of rebound pain after peripheral nerve block subsides, particularly in dense blocks that increase the likelihood of a “dead arm.” Dexamethasone is widely used as an adjuvant to mitigate this, prolonging analgesia and reducing the rebound pain incidence.
3. Ambulatory cPNB Safety
Concerns about discharging patients home with active catheters are increasingly addressed by prospective data. In a prospective study of orthopaedic patients, cPNB was a feasible technique for ambulatory pain control, with low pain scores at 72 hours, a small fraction requiring rescue opioids, and more than three-quarters of patients discharged home with a cPNB in place for 3+ days with high patient satisfaction. No severe complications such as local anaesthetic systemic toxicity (LAST), infection, or permanent neurological damage were reported.
The leakage incidence in ambulatory catheters is low (around 5.9%), and infection rates appear similarly low at approximately 1.2% in supraclavicular and popliteal catheters.
4. Contraindications & Patient Selection for cPNB
Ambulatory cPNB may be inappropriate for patients with known renal and hepatic insufficiency, heart and/or lung disease (among those receiving interscalene blocks), altered mental status or psychosocial issues, inability to be contacted after discharge or to access a medical facility in an emergency, or unwillingness to accept responsibility for pump management.
5. Complications — Site-Specific Data
In a prospective 2023/2024 study of rotator cuff surgery, there were significantly more injection/insertion site complications in the continuous catheter group (48%) versus the single-injection group (11%). On postoperative Day 1, continuous catheter patients had a clinically significantly lower pain score (3.2 vs. 5.4), and all patients in both groups rated satisfaction at 9 or 10 out of 10.
Anaesthetic Agent Preferences
The choice of local anaesthetic profoundly shapes the clinical experience of both block types.
Ropivacaine is the dominant agent for both sPNB and cPNB in ambulatory practice. Agents like ropivacaine, which provide greater sensory-motor separation, are often favoured when prolonged analgesia with reduced motor blockade is desired. For short-duration or ambulatory surgeries, ropivacaine’s shorter motor block duration facilitates earlier mobilisation, potentially reducing complications such as deep vein thrombosis and shortening hospital stays.
For continuous infusions, commonly used concentrations include ropivacaine 0.1%–0.4%, bupivacaine 0.125%–0.15%, and levobupivacaine 0.1%–0.125%. An infusion with ropivacaine 0.1%–0.2% is easier to titrate due to faster resolution of an insensate extremity, though bupivacaine 0.1%–0.125% provides equivalent analgesia at lower cost in most settings.
Bupivacaine, while highly effective, carries greater cardiotoxicity risk and a more pronounced motor block. Although 0.5% bupivacaine is frequently used for postoperative analgesia due to its prolonged duration, it may not be suitable for ambulatory surgery because of the prolonged “dead arm” effect impairing patient independence.
Combination strategies (e.g., lidocaine + ropivacaine or lidocaine + bupivacaine) aim to shorten onset while preserving long duration, though evidence is mixed. Combining lidocaine-epinephrine and ropivacaine reduced the duration of analgesia after an infraclavicular brachial plexus block by approximately five hours — a tradeoff that may suit short-duration procedures where early mobilisation takes priority.
Adjuvants such as dexamethasone (perineural or IV), dexmedetomidine, and clonidine are well-evidenced block-prolonging agents. More than one local anaesthetic can be combined to decrease onset time while providing a longer duration of analgesia.
Practical Clinical Decision Framework
| Clinical Scenario | Preferred Strategy | Preferred Agent |
|---|---|---|
| Minor day-case (e.g., carpal tunnel, knee arthroscopy) | sPNB | Ropivacaine 0.5% ± dexamethasone |
| Major shoulder surgery (rotator cuff repair) | cPNB | Ropivacaine 0.2% infusion |
| Lower limb arthroplasty (ambulatory) | cPNB | Ropivacaine 0.1–0.2% |
| Elderly/fall-risk patient | sPNB (low concentration) | Ropivacaine 0.25–0.375% |
| Patient with poor home support | sPNB | Long-acting agent ± adjuvant |
Key References
- Szamburski et al. Br J Anaesth 2023;130(1):111 — RCT comparing sPNB vs. cPNB patient experience in ambulatory orthopaedics
- Lee JYJ et al. JSES Int 2024;8(2):282–286 — Single vs. continuous interscalene block in rotator cuff repair
- Espinoza AM et al. Eur J Anaesthesiol 2025;42(2) — Prospective safety study of ambulatory CPNB
- Bottomley T et al. BJA Education 2023;23:92–100 — Peripheral nerve catheters for regional anaesthesia
- NYSORA: Continuous PNB — Local anaesthetic solutions and infusion strategies
- StatPearls: Regional Anaesthetic Blocks (NCBI Bookshelf, 2023)
